Loading...

The Scientist

» open access, immunology and disease/medicine

Most Recent

image: Getting Drugs Past the Blood-Brain Barrier

Getting Drugs Past the Blood-Brain Barrier

By Amanda B. Keener | November 1, 2017

To treat neurological disease, researchers develop techniques to bypass or trick the guardian of the central nervous system.

3 Comments

Research in human patients and mice reveals the role of the circadian clock in the risk of heart damage at different times of day.

1 Comment

With the arrival of a new class of single-nucleotide editors, researchers can target the most common type of pathogenic SNP in humans.

1 Comment

image: Opinion: Share Your Data

Opinion: Share Your Data

By Michael P. Milham, Arno Klein, and Cameron Craddock | October 24, 2017

Our analysis of a collection of open-access datasets quantifies their benefit to the scientific community.

2 Comments

image: Genetic Risk Factors for Breast Cancer Identified

Genetic Risk Factors for Breast Cancer Identified

By Ashley P. Taylor | October 23, 2017

Researchers identify 72 novel genetic variants associated with breast cancer risk.

0 Comments

image: FDA Approves Second CAR T-Cell Therapy

FDA Approves Second CAR T-Cell Therapy

By Ashley P. Taylor | October 19, 2017

The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas. 

0 Comments

image: Compound Found in Red Wine Boosts Immune Cell Function

Compound Found in Red Wine Boosts Immune Cell Function

By Catherine Offord | October 17, 2017

At low doses, resveratrol enhanced human T-cell activity in vitro, while at high doses it interfered with cell signaling. 

1 Comment

image: Cancers Relapse by Feeding Off Immune Signals

Cancers Relapse by Feeding Off Immune Signals

By Shawna Williams | October 16, 2017

In mice, the tumor cells are able to thwart the immune response that would kill them—but immunotherapy prevented the return of melanoma.

0 Comments

A needle-free alternative to the finger-prick test would be a godsend for many sufferers of diabetes, but the industry has yet to clear the technological hurdles.

1 Comment

Spark Therapeutics’s Luxturna would be the first approved therapy in the U.S. that replaces or repairs a defective gene inherited from one’s parents.

3 Comments

Popular Now

  1. Estonia Offers Free Genetic Testing to Residents
  2. Human Brain Organoids Thrive in Mouse Brains
  3. RNA Injection Restores Hearing in Guinea Pigs
  4. Jim Bridenstine Confirmed to Lead NASA